Ruxolitinib (S enantiomer)
Based on 3 publication(s) in Google Scholar
Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor.
For research use only. We do not sell to patients.
- Purity: 99.64%
- CAS No.: 941685-37-6
- Formula: C17H18N6
- Molecular Weight:306.37
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ruxolitinib (S enantiomer)
More
Biological Activity
Description
IC50 & Target
|
JAK |
In Vitro
Ruxolitinib (S enantiomer) (S-Ruxolitinib; 10 μM; 12 hours) suppresses IFNβ-induced expression of ISG, IFIT, and IFITM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human small airway epithelial cells (SAECs)
-
Concentration:10 μM
-
Incubation Time:12 hours
-
Result:Suppressed IFNβ-induced expression of ISG, IFIT, and IFITM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female wild-type C57BL/6J or Nes-gfp27 mice with myeloproliferative neoplasms (MPNs) in peripheral blood[2]
-
Dosage:30 mg/kg (in 0.5% hydroxypropylmethylcellulose after solubilisation in DMSO)
-
Administration:Oral gavage; twice per day separated 10-12 h for 8 weeks
-
Result:Reduced haematopoietic cell expansion in MPN but it did not rescue bone marrow (BM) mesenchymal stem cells (MSCs).
Chemical Information
-
CAS No. 941685-37-6
-
Appearance Solid
-
Molecular Weight 306.37
-
Formula C17H18N6
-
Color White to off-white
-
SMILES
N#CC[C@@H](C1CCCC1)N2N=CC(C3=NC=NC4=C3C=CN4)=C2
-
Synonyms
S-Ruxolitinib; S-INCB18424
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Commun Biol
JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells. [Abstract]2021 Jun 2;4(1):654. PMID: 34079039 -
Res Sq
Activation of Interferon-Stimulated Transcriptomes and ACE2 Isoforms in Human Airway Epithelium Is Curbed by Janus Kinase Inhibitors. [Abstract]2020 Dec 11:rs.3.rs-119695. PMID: 33330857 -
bioRxiv
2020 Nov 6:2020.10.04.325415. PMID: 33052350
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (326.40 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
1M HCl : 50 mg/mL (163.20 mM; ultrasonic and adjust pH to 1 with HCl)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hye Kyung Lee, et al. JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells. Commun Biol. 2021 Jun 2;4(1):654. [Content Brief]
[2]. Lorena Arranz, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 7;512(7512):78-81. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| 1M HCl / DMSO | 1 mM | 3.2640 mL | 16.3201 mL | 32.6403 mL | 81.6007 mL |
| 5 mM | 0.6528 mL | 3.2640 mL | 6.5281 mL | 16.3201 mL | |
| 10 mM | 0.3264 mL | 1.6320 mL | 3.2640 mL | 8.1601 mL | |
| 15 mM | 0.2176 mL | 1.0880 mL | 2.1760 mL | 5.4400 mL | |
| 20 mM | 0.1632 mL | 0.8160 mL | 1.6320 mL | 4.0800 mL | |
| 25 mM | 0.1306 mL | 0.6528 mL | 1.3056 mL | 3.2640 mL | |
| 30 mM | 0.1088 mL | 0.5440 mL | 1.0880 mL | 2.7200 mL | |
| 40 mM | 0.0816 mL | 0.4080 mL | 0.8160 mL | 2.0400 mL | |
| 50 mM | 0.0653 mL | 0.3264 mL | 0.6528 mL | 1.6320 mL | |
| 60 mM | 0.0544 mL | 0.2720 mL | 0.5440 mL | 1.3600 mL | |
| 80 mM | 0.0408 mL | 0.2040 mL | 0.4080 mL | 1.0200 mL | |
| 100 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.8160 mL |
Ruxolitinib (S enantiomer) Related Classifications
HY-50856A Related Classifications
Powered by Bioz